
Over the years, physicians have voiced various concerns about the Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis., concerns ranging from the safety of higher doses of olmesartan (Benicar)Medication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. to concerns about long-term antibiotic use. The Autoimmunity Research FoundationNon-profit foundation dedicated to exploring a pathogenesis and therapy for chronic disease. has assembled articles, well-grounded in scientific research, which address these concerns.
Patients on the Marshall Protocol (MP) take olmesartan (Benicar)–a drug whose actions are fully known–every four to six hours. A substantial body of research supports the use of olmesartanMedication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. Also known by the trade name Benicar. as a part of a curative therapy for chronic disease.
Patients on the MP abstain from consumption of vitamin D. Although the secosteroid may currently enjoy a positive reputation in the media, molecular research shows that taking vitamin D exacerbates inflammatory disease.